All News

Convention1.jpg

Preview of EULAR 2019 Abstracts

d Jack Cush, MD

EULAR 2019 begins today in Madrid and features over 2000 presentations.  After an initial review of titles and abstracts, I’ve compiled a hit list of presentations of interest to me and hopefully other practicing rheumatologists.  

Read Article
MAS.jpg

Management of Hemophagocytic Lymphohistiocytosis (HLH) in Adults

d Jack Cush, MD

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome induced by activated macrophages and cytotoxic T cells.  HLH manifests recurrent fever, cytopenia, liver dysfunction, and a sepsis-like syndrome that may complicated by multiple organ failure.

Read Article
gout.MTP1_.jpg

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

d Jack Cush, MD

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.

Read Article
gout.crystal.jpg

Excess Non-CV Mortality Persists in Gout

d RheumNow

Patients with gout not only have a well-recognized increased risk of dying from cardiovascular (CV) disease, but also have higher all-cause mortality and die prematurely from other diseases, a Swedish study indicated.

Read Article
ACR Clean (Keep)

ACR Supports Legislation to Improve Oversight and Transparency of Prior Authorization Use

d Anonymous

Rheumatology Leaders Join a Coalition of National Medical Specialties in Urging Congress to Protect Patients from Prior Authorization Requirements in Medicare Advantage Plans

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – Drug Ad Transparency (6.7.19)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles of note from this past week on RheumNow.com.

Read Article
Looking forward to joining Jack and the rest of the team in reporting for @RheumNow from #EULAR2019 in sunny Madrid this week! https://t.co/WLhaq2KtsR https://t.co/BJGxfDKfcA

Links:

David Liew drdavidliew ( View Tweet)
Plenary session of JIA post TNFI failure OP0016 from 2 UK registries by Kearsley-Fleet shows no difference in 151 kids who go to 2nd TNFi vs switch to different biologic for response and retention. Either is ok. @RheumNow #EULAR2019

Janet Pope Janetbirdope ( View Tweet)

UK study shows SLE admissions increased from 8.97 to 9.04 per 100,000 ( p < 0.001) between 1998 & 2015. By comparison, RA admissions rose from 71.0 to 171.6 per 100,000 ( p < 0.001). YET total bed days for SLE & RA fell by 60% and 90%, respectively https://t.co/5IeZh8o8M5

Links:

Dr. John Cush RheumNow ( View Tweet)

EULAR is a truly pan-European organisation fostering a multitude of activities in areas of research, patient care, and education. Learn more at #EULAR2019! #rheumatology #rheumarthritis #lupus https://t.co/sGSuKnXpNg
EULAR | The European League Against Rheumatism eular_org ( View Tweet)
NHANES study shows Psoriatic arthritis found that #PsA patients report more hearing difficulties (OR 1.50, p 0.043), visit mental health provider (OR 1.62, p = 0.084), 1.62 more days of poor mental health (p = 0.033), and depression (OR 2.01, p = 0.015) https://t.co/xdh4MfWxbA

Links:

Dr. John Cush RheumNow ( View Tweet)

https://t.co/V10S4oVFsv would love to feature your tweets in our coverage of #EULAR2019 from Madrid. Be sure to include these 3 in your tweet- @RheumNow #EULAR2019 & the abstract # https://t.co/WqqX4w4dmd

Links:

Dr. John Cush RheumNow ( View Tweet)
GSK announced that the FDA has approved the IL-5 inhibitor Nucala (mepolizumab), as an autoinjector and a pre-filled safety syringe, (for use in severe eosinophilic asthma & disease eosinophilic granulomatosis with polyangiitis (EGPA) https://t.co/XXGJxLDta7

Links:

Dr. John Cush RheumNow ( View Tweet)

Hear nine experts talk about biosimilars in “Therapeutic Update: Biosimilars in Rheumatology”, a video series brought to viewers by Sandoz. Now available on RheumNow. https://t.co/1vmnEJqOSi #sponsored #biosimilars

Links:

Dr. John Cush RheumNow ( View Tweet)

US Dermatologists serving on FDA advisory panels during derm drug approval: study shows half received at least 1payment from pharma; 27% > $1000, 15% >$50K, 9% > $100K. Payments from competitors outnumbered manufacturers https://t.co/bNmjkQFOJM

Links:

Dr. John Cush RheumNow ( View Tweet)

The cost of healthcare in inflammatory bowel disease is >3 times a healthy population. Overall, average annual costs for patients with IBD were $22,987 compared with $6,956 without IBD, the study found. Out-of-pocket costs were more than doubled . https://t.co/FopLzw4ypU

Links:

Dr. John Cush RheumNow ( View Tweet)

https://t.co/V10S4oVFsv would love to feature your tweets in our coverage of #EULAR2019 from Madrid. Be sure to include these 3 in your tweet- @RheumNow #EULAR2019 & the abstract # https://t.co/WqqX4w4dmd

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast is up! Info on Drug Ad Transparency, FDA CBD oil hearing, OI, TB testing, Stem Cell Clinics and more. Watch it here >>https://t.co/MbE91908Er or listen to the podcast on iTunes or SoundCloud >> https://t.co/FbEn1vWriU

Links:

Dr. John Cush RheumNow ( View Tweet)

Clinical Trials Benchmark for Biosimilar Development is one of several educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi #sponsored #biosimilars

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - daily lessons and cases from the Rheumatology clinic. RA patient, not quite controlled, needs to optimized MTX therapy Features Dr. Jack Cush https://t.co/ZoX2biwv7M

Links:

Dr. John Cush RheumNow ( View Tweet)

×